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Abstract: Recently, we serendipitously discovered that mice with the deficiency of the enzyme 
prolylcarboxypeptidase (PRCP) have elevated α-melanocyte-stimulating hormone (α-MSH) 
levels which lead to decreased food intake and weight loss. This suggests that PRCP is an 
endogenous inactivator of α-MSH and an appetite stimulant. Since a modest weight loss can 
have the most profound influence on reducing cardiovascular risk factors, the inhibitors of PRCP 
would be emerging as a possible alternative for pharmacotherapy in high-risk patients with 
obesity and obesity-related disorders. The discovery of a new biological activity of PRCP in the 
PRCP-deficient mice and studies of α-MSH function indicate the importance and complexity 
of the hypothalamic pro-opiomelanocortin (POMC) system in altering food intake. Identifying 
a role for PRCP in regulating α-MSH in the brain may be a critical step in enhancing our 
understanding of how the brain controls food intake and body weight. In light of recent findings, 
the potential role of PRCP in regulating fuel homeostasis is critically evaluated. Further studies 
of the role of PRCP in obesity are much needed.
Keywords: prolylcarboxypeptidase, melanocyte-stimulating harmone, appetite, weight loss, 
cardiovascular risk, obesity
Introduction
The hypothalamus is often times a target for newer potential obesity treatments due 
to its crucial role in food intake and metabolism. It is also established that food intake 
modulation is confounded by numerous players within the hypothalamus, allowing 
for the research and development of a diverse array of obesity management drug leads 
that have completely different underlying mechanisms. The melanocortin system is 
established amongst these systems; however, the cannabinoid system, among others, 
also has an established role. Speculation of a connection between the cannabinoid sys-
tem and melanocortin system regarding food intake has existed due to their presence 
in nearby regions of the hypothalamus. Moreover, suboptimal doses of SR 141716 
(rimonabant) together with suboptimal doses of α-melanocyte-stimulating hormone 
(α-MSH) are known to behave synergistically in order to reduce food intake. Attempts 
to develop a safe drug to treat obesity via blocking the CB1 receptor have proven to 
be elusive and controversial, as drugs such as rimonabant have had to struggle for 
approval due to numerous reported and suspected side effects, particularly depression. 
The role of the melanocortin system in food intake is well-established and preven-
tion of the rapid inactivation of α-MSH may prove to be a better alternative pathway 
for potential obesity treatments. Recent studies suggest that prolylcarboxypeptidase 
(PRCP) involved in regulating blood pressure and inflammation is an appetite stimulant Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 68
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and, by consequence, PRCP inhibitors may prove to be a 
viable lead to treat obesity.
There have been numerous excellent reviews on 
melanocortin receptors.1–6 However, this article only reports 
the most current information about how the two tectonic 
physiological processes, namely the proteolytic enzymes of 
renin-angiotensin system (RAS) and proopiomelanocortin 
(POMC)-derived neuropeptide regulatory processes in the 
central nervous system might be shifting toward each other. 
Recent findings suggest that PRCP (a RAS enzyme) regulates 
α-MSH (a POMC-derived neuropeptide) levels, a theme 
addressed by the present review. While this article briefly 
introduces both PRCP- and α-MSH-mediated processes, 
it also outlines how brain PRCP may play a key role in 
controlling food intake and weight gain.
The current scope  
of prolylcarboxypeptidase
The PRCP-catalyzed reaction was initially found to be part of 
the pathway for angiotensin II (Ang II) metabolism in renal 
tissues, where PRCP appeared to control the total amount of 
Ang II. Odya and others demonstrated that PRCP metabolizes 
Ang II to angiotensin 1–7 (Ang 1–7) (Figure 1).7 The activation 
of Ang 1–7 receptor Mas (a G-protein-coupled protein) by 
Ang 1–7 results in the generation of nitric oxide (NO) and 
prostaglandins.8 Thus, Ang 1–7 counteracts Ang II function, 
providing evidence that PRCP regulates the negative effects 
of Ang II such as high blood pressure and heart failure.9 In 
addition, the activation of the Ang 1–7 receptor Mas may also 
lead to diminished cell proliferation through down-regulation 
of the phosphorylation and activation of Erk1 and Erk2 in the 
Erk1/Erk2 Map kinase signaling pathway.10,11 In theory, the 
PRCP inhibitors to target the production of pro-inflammatory 
prostaglandins and promote proliferation through the Ang 1–7 
receptor Mas-dependent pathway represent a novel approach to 
suppress unwanted inflammation-causing prostaglandins.
Later, it was shown that PRCP is one of several enzymes 
that convert Ang II to a unique bioactive molecule. In vitro 
studies showed that angiotensin-converting enzyme 2 (ACE2) 
is an exopeptidase that converts Ang II to Ang 1–7 at a much 
faster rate than PRCP.12 These data suggest that Ang II is a 
poor substrate for PRCP. Clinical studies have provided reli-
able evidence that ACE2 is an essential regulator of angio-
tensin I (Ang I), Ang II, and angiotensin-induced cardiac 
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Figure 1 The physiological action of prolylcarboxypeptidase (PRCP).
Notes: PRCP elicits increased production of proinflammatory prostaglandins and vasodilatory nitric oxide and promotes orexigenic action through inactivation of α-MSH.
Abbreviations: α-MSH, α-melanocyte-stimulating hormone; HK high molecular weight kininogen; PK, prekallikrein.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 69
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hypertrophy.13 Recent studies clearly show increased myo-
cardial levels of Ang II and a significant decrease in Ang 1–7 
in ACE2-deficient hearts, suggesting that the role of PRCP 
in metabolizing Ang II may be insignificant.9 Taken together, 
these observations suggest that PRCP is a redundant catalyst 
contributing to alternate pathways for Ang II metabolism.
While the well-established cardiovascular and renal actions 
of Ang II are attributed to the angiotensin type 1 receptor 
(AT1R), much less is known about angiotensin III and its 
cardiovascular effects. For more than 30 years, it was known 
that PRCP metabolizes Ang III to Ang 2–7 (Figure 1).7 Soon 
after, studies demonstrated that Ang III is a pressor agent whose 
response, like that of Ang II, is mediated by AT1 receptors.14,15 
Apparently, Ang III has multiple effects on renal function in 
the diseased kidney and can enhance renal disease through the 
overproduction of aldosterone, leading to arterial hypertension 
and/or atrial fibrillation.16 Aldosterone maintains blood volume, 
pressure, and electrolyte balance. Its production is known to be 
regulated by renin, an enzyme produced in the kidneys. Renin 
increases in response to low blood pressure, decreased blood 
flow to the kidneys, or sodium deficiency. The elevation of renin 
results in an increase in synthesis and secretion of aldosterone. 
Studies indicate that Ang III also activates the secretion of 
aldosterone.15 Recently, we have demonstrated that recombinant 
PRCP (rPCRP) metabolizes Ang III to Ang 2–7, removing phe-
nylalanine (Phe).8 It is tempting to speculate that PRCP might 
funnel the generation of angiotensin 3–4 (Ang 3–4) through Ang 
2–7 (Figure 1). If the over-secretion of aldosterone by Ang III 
is viewed as a trigger of arterial hypertension, then inactivation 
of Ang III by PRCP might lead to a decrease in blood pressure. 
Further studies are required to determine whether PRCP is criti-
cally important for regulating Ang III-induced hypertension and 
preserving renal structure and function. This is an important 
area of research to pursue given the increasing prevalence of 
cardiovascular disease and stroke in the older population.
The possible actions of another substrate of PRCP, 
plasma prekallikrein (PK, Fletcher factor), have recently 
begun to receive much attention. When the complex of 
high molecular weight kininogen (HK) and PK binds to 
endothelial membrane, PK is rapidly converted to kallikrein 
by PRCP.17 The formed kallikrein then cleaves HK to liberate 
bradykinin (BK), which leads to NO and prostaglandin-I2 
formation, as well as subsequent vasodilation, by activating 
constitutive bradykinin B2 and inducible bradykinin B1 
receptors.18,19 The PRCP-dependent PK activation pathway 
might be considered an additional mechanism to preserve the 
availability of NO and prostacyclin as vasodilatory agents in 
vascular smooth muscle. We proposed that chronic PRCP 
inhibition might elevate blood pressure. In accordance, we 
have found that PRCPgt/gt mice have mild hypertension, sug-
gesting a causative relationship between PRCP levels and 
signs of hypertension.20
Local skeletal muscle ischemia and acidosis are shown 
to increase the generation of BK and prostaglandins, the two 
circulating products of the PRCP-induced cell activation 
(Figure 1).21 The increased acidotic response during exercise 
and inflammatory mediators such as BK and prostacyclin 
have been shown to cause abnormal exercise-related 
symptoms and autonomic responses in congestive heart 
failure syndrome.22 Nonetheless, the long-term elevated con-
centrations of NO and prostacyclin through PRCP-dependent 
pathways may be detrimental and eventually responsible for 
cardiovascular diseases such as congestive heart disease. 
Since BK and Prostaglandins exacerbate the genesis of 
the symptoms of exercise intolerance in heart failure,23 the 
inhibitors of PRCP might be effective in ameliorating the 
exercise-limiting symptoms.
Clinical studies demonstrate that PRCP is involved in 
the pathogenesis of inflammatory conditions such as rheu-
matoid arthritis and infection.24 Melanocortin peptides have 
numerous effects on the host such as the modulation of 
fever, inflammation and appetite.25 Recently, we showed that 
PRCP metabolizes alpha-melanocyte-stimulating hormone 
1–13 (α-MSH1–13) to alpha-melanocyte-stimulating hor-
mone 1–12 (α-MSH1–12),26 (Figure 1). α-MSH1–13 is a potent 
anti-inflammatory agent.27 In addition to the specificity of 
cleavage, the cellular release of pro-inflammatory mediators 
seemed to be critical to PRCP actions. In theory, agents that 
increase production and effects of α-MSH1–13 could be used 
to counteract the effects of pro-inflammatory mediators such 
as bradykinin and cytokines (Figure 1).
Obesity is known to cause inflammation and insulin 
resistance in the vasculature and non-vascular tissues 
involved in glucose metabolism.28 Evidence suggests that 
hyperglycemia may contribute to defective NO-dependent 
vasodilation in diabetes.29 The inducible NO synthase 
(iNOS) expression is elevated in adipose tissue of obese 
people compared to those of lean people30 and is a mediator 
of inflammation and a key enzyme in insulin resistance.31 
The colocalization of α-MSH1–13 receptors (MC4R) with 
iNOS has been reported, suggesting a role for α-MSH1–13 in 
obese people.32 The inactivation of α-MSH1–13 by PRCP pro-
vides a positive feedback loop for postprandial enhancement 
of food intake and inflammation by inhibiting α-MSH1–13 
function, as shown in Figure 2.26 Since PRCP regulates 
the anorectic action of α-MSH1–13, this study highlights Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 70
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the presence of a newly recognized interaction between 
inflammation, obesity, and the expression and activity of 
PRCP (Figure 2).26 In view of the above studies, we consider 
that PRCP may be a key player in the obesity-associated 
metabolic complications, inflammatory response, and the 
host defense mechanism.
Prolylcarboxypeptidase’s physiological 
function and relationship with 
hypothalamic appetite-regulating 
pathways
The following sections emphasize pertinent findings, which 
best describe the theoretical perspective on the components 
of the central melanocortin system and stress the importance 
of PRCP influence in the melanogenic signaling pathway.
Synthesis of α–melanocyte – stimulating hormone
Pro-opiomelanocortin (POMC), a prohormone with molecular 
weight of 31 kDa, is ubiquitously expressed in various tissues of 
mammals.33,34 POMC expression in the central nervous system, 
however, is limited to the arcuate nucleus of the hypothalamus 
(ARC), nucleus tractus solitarius of the caudal medulla (NTS), 
and corticotrophs and melanotrophs of the anterior pituitary 
(Figure 2).35 The 1200 base pair POMC transcript encodes 
for the 267 amino acid prohormone with an N-terminal signal 
peptide of 26 residues.36 As this precursor peptide passes through 
the Golgi stacks, it is targeted, via a specific signal peptide, into 
regulated secretory granules.37 POMC undergoes extensive 
posttranslational modification within these secretory granules 
mediated by a family of serine proteases, the prohormone 
convertases (PCs), as illustrated in Figure 3.
POMC is cleaved by prohormone convertase 1 (PC1) to 
produce 22 kDa pro-ACTH and β-lipoprotein hormone (β-LPH) 
(Figure 3).38 Pro-ACTH is further cleaved by PC1 to produce 
the N-terminus of POMC-joining peptide and 4.5 kDa ACTH. 
Prohormone convertase 2 (PC2) cleaves ACTH to ACTH 1–17 
and corticotropin-like intermediate lobe peptide (CLIP) and 
β-LPH to γ-lipoprotein hormone (γ-LPH) and β-endorphin 
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Figure 2 The role of the hypothalamus in food intake and metabolism.
Notes: The catalysis of α-MSH1–13 to α-MSH1–12 by PRCP leads to increased food intake and body weight gain in humans. Blue arrows indicate anorectic response and red 
arrows indicate orexigenic response.
Abbreviations: Act-α-MSH, acetylated α-MSH; AgRP, Agouti-related protein; ARC, arcuate nucleus of the hypothalamus; Des-α-MSH, desacetyl α-MSH; DM, dorsomedial 
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(Figure 3). γ-LPH and the N-terminus of POMC are further 
modified to produce β-MSH and γ-MSH, respectively.
α-MSH is a tridecapeptide derived from POMC. The 
synthesis of α-MSH from POMC involves several specific 
enzymes in addition to PC1 and PC2. First, carboxypeptidase 
E cleaves the C-terminal basic amino acid residues of 
ACTH 1–17. The peptide is then amidated by peptidyl 
α-amidating monooxygenase (PAM) to produce desacetyl 
α-MSH (Des-α-MSH). Finally, Des-α-MSH is acetylated 
by N-acetyltransferase (NAT) to produce acetylated α-MSH 
(Act-α-MSH), as illustrated in Figure 2. Act-α-MSH is more 
potent than Des-α-MSH in activating melanocortin receptor 
signaling and in reducing food intake, effects that are likely 
due to rapid degradation of Des-α-MSH. Guo et al have 
shown that total hypothalamic α-MSH levels are decreased 
in leptin-deficient ob/ob mice and increased in leptin-treated 
ob/ob and C57BL/6J mice. Leptin specifically enhances 
hypothalamic levels of Act-α-MSH without significantly 
affecting the amounts of Des-α-MSH, possibly by activating 
NAT in the POMC neurons.39
Five distinct central melanocortin receptors  
with different physiological functions
The melanocortin receptors are G-protein-coupled receptors 
with characteristic seven transmembrane domains. So 
far, five melanocortin receptors have been identified in 
humans – MC1R–MC5R.40–43 The melanocortin receptors are 
Gs-coupled and signal via the adenylate cyclase-cAMP-protein 
kinase A second messenger pathway. However, depending on 
the cell type and the melanocortin receptor expression, signal 
transduction pathways other than cAMP may be activated 
which include inositol triphosphate-diacyl glycerol-protein 
kinase C (IP3-DAG-PKC) pathway, extracellular Ca2+ influx, 
MAP kinase pathway, and the JAK/STAT pathway.44–48 
MC1R, MC3R, MC4R and MC5R show 40%–60% amino 
acid homology. The natural MSH peptides have a conserved 
sequence, His-Phe-Arg-Trp, which plays an important role 
in the binding of these peptides to specific melanocortin 
receptors.49
MC1R was the first melanocortin receptor to be cloned 
and was isolated from human melanoma cell line.40 α-, β- and 
γ-MSH and ACTH are the known agonists whereas agouti 
is the known antagonist of the MC1R. MC1R is expressed 
in human and mouse melanoma cells, human melanocytes, 
skin glands, and hair follicles.40,50–53 α-MSH, agouti, and 
MC1R, therefore, play an important role in regulating skin 
pigmentation and hair color. The presence of MC1R in the 
testes and the pituitary has been demonstrated by Chhajlani 
et al.54 MC1R expression in the central nervous system is 
limited to neurons of the periaqueductal grey in both rat and 
human brain.55 However, MC1R is widely expressed in cells 
involved in inflammation such as endothelial cells, neutrophils, 
monocytes, macrophages, fibroblasts and astrocytes.25,56–59 
α-MSH has been shown to inhibit inflammation via 
MC1R-mediated decrease in the production of inflammatory 
cytokines such as IL-1, IL-6, and tumor necrosis factor-alpha 
(TNFα), as well as suppression of NF-κB.60–62
MC2R is encoded by a single gene localized to chromosome 
18p11.2.53 ACTH is the only known agonist of the MC2R.63 
Using in situ hybridization, Xia et al showed that MC2R is 
highly expressed in the adrenal cortex with the highest expres-
sion in the zona fasciculata and zona glomerulosa and rela-
tively low expression in the zona reticularis.64 These findings 
are consistent with the role of MC2R in mediating the effect of 
ACTH on the synthesis and release of corticosteroids. Besides 
the adrenal cortex, MC2R is expressed in murine adipocytes, 
which explains the lipolytic effect of ACTH.59 However, 
human adipocytes do not express MC2R and there is no evi-
dence to suggest that human adipose tissue is responsive to 
the lipolytic effect of ACTH.54 These species differences in 
the expression of MC2R may be important when studying the 
role of melanocortins in obesity. MC2R expression has also 
been demonstrated in the skin along with three cytochrome 
enzymes involved in steroid hormone synthesis.65 Kapas et al 
have shown that ACTH produced in the skin by keratinocytes 
stimulates DNA synthesis and induces cell proliferation via 
MC2R.66 MC2R, therefore, appears to play an important role 
in cutaneous pathophysiology.
ACTH
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Figure 3 Schematic structure of pro-opiomelanocortin (POMC) and location of melanocyte-stimulating hormones (MSH).
Abbreviations: ACTH, adrenocorticotropic hormone; β-LPH, beta-lipotropic hormone; S, signal sequence; γ-MSH, gamma-MSH; α-MSH, alpha-MSH; β-MSH, beta-MSH; 
β-endorphin, beta-endorphin.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 72
Shariat-Madar et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
MC3R is encoded by a single gene localized to the 
q13.2–q13.3 region of chromosome 20.67 Since this locus 
is associated with type 2 noninsulin-dependent diabetes 
mellitus (NIDDM), Mc3r could represent a candidate 
gene for NIDDM.68 MC3R is unique in that it binds to 
α-, β- and γ-MSH with similar affinities. Using Northern 
blot hybridization and polymerase chain reaction, Gantz et al 
first showed that MC3R is expressed in brain, placental, and 
gut tissues but not in melanoma cells or in adrenal glands.69 
MC3R expression in the brain is highest in the hypothalamus 
especially in the arcuate nucleus, ventromedial nucleus, 
preoptic nucleus, lateral hypothalamic area, and posterior 
hypothalamic area.43 Agouti-related protein (AgRP), which 
is normally expressed in the hypothalamus, is a potent 
antagonist of both MC3R and MC4R.70 However, POMC and 
AgRP neurons in the arcuate nucleus of hypothalamus selec-
tively express MC3R, and not MC4R, suggesting that MC3R 
might function as a presynaptic autoreceptor regulating the 
release of melanocortins.71,72 Physiological support for this 
hypothesis was provided by Cowley et al,73 who demonstrated 
that the selective MC3R agonist, D-Trp-γ-MSH inhibited fir-
ing of GFP-labeled POMC neurons in the PVN. Also, Marks 
et al showed that peripheral administration of the MC3R 
agonist stimulates feeding via MC3R-mediated inhibition 
of the ARC POMC neurons.74
An association between MC3R and human obesity has 
been identified by linkage studies. Several sequence variants 
have been found in the Mc3r coding region and in 5' flanking 
sequences.75 Mc3r variants are associated with subtle changes 
in weight, leptin levels, and insulin-glucose ratios, but none of 
these explain human morbid obesity.76 A novel heterozygous 
mutation I183N in Mc3r was identified in two obese patients 
of the same family.77 Functional characterization of I183N 
showed that this mutation completely abolished the activity of 
the mutated receptor to stimulate intracellular cAMP produc-
tion, suggesting that I183N might play an important role in 
obesity.78 Similarly, Tao et al showed that a novel mutation 
I335S in Mc3r results in complete loss of ligand binding and 
signaling suggesting that this mutation might contribute to 
obesity.79 However, a recent study evaluating the functional 
consequences of all mutations found in Mc3r and Mc4r in 
severely obese North American adults concluded that Mc4r, 
but not Mc3r mutations are associated with severe obesity in 
this population.80 Thus, the significance of Mc3r mutations in 
human obesity is still not conclusively established to date.
MC4R was first cloned by Gantz et al in 1993.42 MC4R is 
a 332 amino acid protein encoded by a single gene, localized 
to chromosome 18q21.3. Using Northern blot analysis and 
in situ hybridization, MC4R was originally found to be 
expressed primarily in the brain. MC4R expression was 
notably absent in the adrenal cortex, melanocytes, and 
placenta.42 MC4R is widely distributed in the central nervous 
system, especially in the cortex, hippocampus, amygdala, 
septum, corpus striatum, nucleus accumbens, hypothalamus, 
nucleus tractus solitarius, visual and motor nuclei of the 
brainstem, and the dorsal horn of the spinal cord.81 α- MSH, 
β-MSH, and ACTH are the known agonists and AgRP is the 
known antagonist of the MC4R (Figure 2).70
Since MC4R is highly expressed in the hypothalamus and 
has a strong affinity for α-MSH it is believed to be a strong 
candidate for energy balance, appetite control, and body 
weight regulation. Mc4r knockout mice have been shown to 
develop a maturity onset obesity syndrome characterized by 
hyperphagia, hyperglycemia and hyperinsulinemia.82 Since 
this syndrome is similar to the agouti obesity syndrome seen 
in Avy/– mice and AgRP-transgenic mice that overexpress 
agouti and AgRP respectively, it is speculated that the primary 
mechanism by which agouti and AgRP produce obesity is 
chronic antagonism of MC4R.83 Cachexia, a chronic wasting 
syndrome characterized by loss of body weight and muscle 
mass, is commonly associated with diseases such as cancer 
and AIDS. MC4R–/– mice and mice treated with AgRP are 
resistant to lipopolysaccharide- or tumor-induced cachexia, 
further supporting the role of MC4R in energy balance and 
body weight regulation.84
MC5R is a 325 amino acid protein encoded by a single 
gene located on chromosome 18p11.2.85 MC5R has been 
shown to bind to all melanocortins except γ-MSH.86 MC5R 
is the most widely expressed melanocortin receptor. MC5R 
mRNA is expressed in the adrenal gland, adipose tissue, 
kidney, leukocytes, lung, lymph node, mammary gland, ovary, 
pituitary, testis, and uterus.54 Mc5r is highly expressed in 
exocrine glands such as lacrimal, preputial, Harderian and 
sebaceous glands.87 Mc5r-deficient mice have a severe defect 
in water repulsion and thermoregulation due to decreased 
production of sebaceous lipids. MC5R may therefore play 
an important role in peripheral thermoregulation. Stud-
ies in humans have shown that MC5R immunoreactivity 
is detectable in the epithelium and appendages, including 
the sebaceous, eccrine, and apocrine glands. However, 
analysis of Mc5r variations in patients with acne, hidradenitis 
suppurativa, and sebaceous gland dysfunction have failed 
to suggest a causative role of MC5R in these conditions.88 
Low levels of MC5R mRNA have also been reported in the 
central nervous system,89 however, the physiological function 
of MC5R in the brain remains unclear. Linkage analysis in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 73
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the Quebec Family Study90 revealed a significant association 
of Mc5r polymorphisms with body mass index, fat mass, 
and resting metabolic rate, thus providing some evidence 
for the possible role of MC5R in energy balance and body 
weight regulation.
Appetite is tightly controlled by the relative 
hypothalamic levels of α-MSH
ARC is the major site of POMC expression in the central 
nervous system. The POMC neurons, which produce 
α-MSH, also express another anorectic peptide cocaine-
amphetamine-related transcript (CART). Cell bodies of the 
POMC/CART neurons are found throughout the rostrocaudal 
extent of the arcuate nucleus, as well as the periarcuate 
area of the hypothalamus. Within the hypothalamus, these 
neurons project to the periventricular nucleus, paraventricular 
nucleus (PVH), and the perifornical region.91,92 The 
POMC/CART neurons also project to the brainstem 
to innervate the rostral NTS, lateral reticular nucleus, 
ventrolateral medulla, nucleus ambiguous, and the spinal 
cord, as reviewed elsewhere.93 Another critical component 
of the central melanocortin system within the ARC is the 
neurons expressing neuropeptide Y (NPY) and the potent 
MC3R/MC4R antagonist AgRP (Figure 2). The NPY/AgRP 
neurons have the same distribution as the POMC/CART 
neurons within the hypothalamus, with the densest fibers 
innervating the PVH, dorsomedial hypothalamus (DMH), 
posterior hypothalamus, and septal regions around the 
anterior commissure.94
The NPY/AgRP neurons form synapses with the POMC/
CART neurons within the ARC, thus producing a neuronal 
network that is responsive to the modulatory effects of several 
appetite and body weight regulating hormones such as leptin, 
ghrelin, insulin, and peptide YY (PYY).73,95–98 Leptin acts 
via hypothalamic receptors (Ob-R) to decrease feeding and 
increase thermogenesis, resulting in a decrease in body weight. 
POMC/CART and NPY/AgRP neurons in the ARC are the 
principal sites of leptin receptor expression and the source 
of potent neuropeptide hormones, α-MSH and NPY, which 
exert opposing effects on feeding and metabolism as shown 
in Figure 2. Subpopulations of NPY/AgRP neurons that also 
express gamma-aminobutyric acid (GABA) send inhibitory 
collaterals to the POMC/CART neurons. GABA inhibits 
the POMC/CART neurons and blocks the anorexic effect of 
α-MSH (Figure 2).99 Using electrophysiological techniques, 
Cowley et al showed that leptin stimulates the POMC/CART 
neurons via two mechanisms: 1) depolarization through 
a nonspecific cation channel and 2) hyperpolarization of 
NPY/AgRP neurons, leading to a reduction in the release of 
GABA that, in turn, causes disinhibition of the POMC/CART 
neurons (Figure 2).73
Ghrelin, the endogenous ligand for growth hormone 
secretagogue receptor (GHS-R), is a potent stimulant of 
growth hormone release and plays an important role in 
appetite control and body weight regulation. Circulating 
ghrelin levels are markedly increased with fasting and before 
meals and decrease following meals.100,101 Plasma ghrelin 
levels are also influenced by long-term energy balance and 
are increased in anorexia and decreased in obesity.102,103 
Within the ARC, GSH-R is expressed on the NPY/AgRP 
neurons which are thought to mediate the orexigenic effects 
of ghrelin. Central and peripheral administration of ghrelin 
induces c-Fos in these neurons and increases hypothalamic 
NPY and AgRP mRNA expression, thus antagonizing the 
anorexic effects of leptin.95,98,104 Also, electrophysiological 
studies have shown that ghrelin directly activates the 
orexigenic NPY/AgRP neurons while coordinately inhibiting 
the anorexogenic POMC/CART neurons via increased 
GABA release on them (Figure 2).105 Stimulation of food 
intake by ghrelin is blocked by administration of NPY 
antagonist and is reduced in NPY–/– mice.95 Lastly, MC3R and 
MC4R knockout mice show reduced sensitivity to ghrelin 
as evidenced by decreased ghrelin-induced food intake and 
growth hormone secretion, thus suggesting an important role 
of MC3R and MC4R in mediating the orexigenic effects of 
ghrelin.106
NPY is a potent hypothalamic orexigenic pep-
tide, probably the most powerful stimulant of appetite 
known. NYP mRNA expression in the hypothalamus is 
significantly increased during lactation and fasting.107 Cen-
tral administration of NPY causes robust increase in food 
intake and body weight in rats.108,109 Chronic intracerebro-
ventricular administration of NPY to normal rats produces 
hyperphagia, hyperinsulinemia, and liver and adipose tissue 
lipogenesis, thus mimicking the hormonal and metabolic 
changes of obesity.110 Recent evidence suggests that ectopic 
overexpression of NPY in other areas of the hypothalamus 
such as PVH, lateral hypothalamus, and DMH also increases 
food intake and body weight and that NPY knockdown in 
the DMH ameliorates the hyperphagia, obesity, and diabetes 
of Otsuka Long-Evans Tokushima Fatty (OLETF) rats.111,112 
Thus, NPY in the hypothalamus plays an important role in 
modulating food intake and body weight (Figure 2).
NPY exerts its orexigenic effects probably by inhibiting 
the ARC POMC/CART neurons via its Y2 receptor.113 NPY 
is metabolized by several peptidases in the plasma. Recent Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 74
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evidence suggests that NPY(1–36) is metabolized into three 
major fragments: NPY(3–36), NPY(3–35), and NPY(2–35), 
upon incubation with human serum.114 Specific inhibitors of 
dipeptidyl peptidase 4, plasma kallikrein, and aminopepti-
dase P prevent the production of NPY(3–36), NPY(3–35), 
and NPY(2–36), respectively. Plasma kallikrein metabolizes 
NPY(3–36) to NPY(3–35). Since NPY(3–35) is unable to 
bind to NPY Y1, Y2, and Y5 receptors, NPY(3–35) may 
represent the major metabolic end product of the Y2/Y5 
agonist, NPY(3–36).
Insight into the physiological functions  
of PRCP through genetic studies in mice
A recent study identified two splice variants of PRCP; the 
second isoform was named Prcp2 (NCBI: NM_199418). 
Unlike Prcp, Prcp2 has a longer transcript and a unique 
amino-terminal region. Although its full-length sequence 
is known, there is no evidence suggesting whether PRCP2 
mRNA encodes a functional protein.24
The Prcp gene is speculated to be a candidate gene 
for essential hypertension.115 Mutational analysis of 
the human PRCP has led to a better understanding of 
PRCP-catalyzed reactions. Certain putative mutant forms 
of human PRCP apparently predispose the polymorphic 
carriers to cardiovascular diseases including hypertension 
and the risk of preeclampsia.116 The E112D polymorphism 
in the Prcp gene leads to increased antihypertensive effect of 
benazepril treatment in hypertensive patients.117 We have also 
demonstrated that PRCPgt/gt mice have mild hypertension.20 
Our recent studies demonstrated that the Prcp-null (PRCP–/–) 
mice ate less and had even less fat than the mice with partial 
loss of the enzyme.26 These observations suggest that PRCP 
is a genetic marker for weight regulation and putative PRCP 
single nucleotide polymorphism (SNP) variants are associated 
with mild hypertension. Continued identification of PRCP 
mutations, full-characterization of PRCP knockout mice, and 
studies with knock-in mice with PRCP/PRCP mutations will 
provide evidence that PRCP is a disease-causing gene for 
both obesity and hypertension. Meanwhile, we propose that 
the use of PRCP inhibitors should be strongly indicated by a 
diagnosis of obesity in patients with no systolic or diastolic 
deterioration.
Future perspectives
Obesity is an emerging worldwide public health hazard and is 
associated with significant morbidity and mortality. Although 
the physiological determinants of normal/abnormal eating 
behavior have been investigated, the underlying causes and 
mechanisms of dysregulation of food intake in obesity, type 
2 diabetes, and metabolic syndrome are not well understood. 
The long-lasting challenge for clinicians and scientists in 
basic research to unfold the major cause of the dysregulation 
of the food intake is becoming close to the last battle. Clinical 
studies indicate that the molecular and cellular mecha-
nisms by which leptin and alpha-melanocyte stimulation 
hormone (α-MSH) modulate each other’s activity result 
in the regulation of food intake and energy expenditure.118 
These studies suggest that α-MSH is intimately involved in 
the regulatory mechanism of obesity, energy expenditure, 
and body weight.
Recently, prolylcarboxypeptidase (PRCP) was found 
to be responsible for the control of food intake and energy 
expenditure at a central level. The molecular mechanisms 
underlying the suppression of food intake in PRCP-deficient 
mice or by the inhibitor of PRCP clearly provide physiological 
evidence that PRCP is an inactivator of α-MSH.26 Thus, 
PRCP is emerging as a new identity involved in the control 
of food intake and energy metabolism.
Since α-MSH can activate both melanocortin 4 receptors 
(MC4R) and melanocortin 1 receptors (MC1R) in a decreasing 
order, the catalysis of α-MSH1–13 to α-MSH1–12 by PRCP 
would lead to the suppression of both MC4R and MC1R 
activation as shown in Figure 4. Although there are various 
contributing factors for obesity, the recent research findings 
indicate that PRCP is involved in the development of weight 
gain and obesity. PRCP controls the balance between energy 
intake and energy expenditure via an α-MSH1–13-mediated 
mechanism. An increase in PRCP expression or activity 
may result in obesity due to an imbalance between energy 
intake and energy expenditure. Although regulation of 
α-MSH1–13-mediated MC4R activation described above is 
demonstrably important, the importance of the role of PRCP 
on the signaling mechanisms of MC1R in anti-inflammatory 
response remains an enigma (Figure 4).119 Additional studies 
are needed to determine whether or not PRCP regulates 
α-MSH1–13-mediated MC1R activation.
The cellular role of PRCP is beginning to be unraveled 
both at the molecular and physiological levels. The human 
PRCP mutation studies exhibit associations with diseases 
such as hypertension and preeclampsia. The upregulation 
of human PRCP expression during inflammation has been 
described.24 On other hand, the PRCP knockout mice study 
demonstrates that PRCP is an appetite stimulant. Therefore, 
the pleiotropic effects of PRCP include increased NO and 
prostaglandin bioavailability, decreased vasoconstriction, 
and increased appetite.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 75
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In summary, knowledge of the role of PRCP in mouse 
appetite regulation has provided a new view of the ability 
of PRCP to influence obesity. Thus, research on PRCP-α-
MSH interactions may be important to the further under-
standing of human obesity. In addition, the identification 
of PRCP as an inactivator of α-MSH should provide an 
attractive therapeutic target in the fight against obesity. 
However, due to its pleiotropic effects, the PRCP inhibitors 
must be scrutinized carefully to optimize their use in the 
treatment and prevention of obesity and obesity-related 
diseases.
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